Corvus Pharmaceuticals, Inc.

CRVS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$8,740$12,620$13,159$63,458
Short-Term Investments$43,224$14,529$29,144$5,993
Receivables$216$63$633$539
Inventory$0$0$0$0
Other Curr. Assets$2,227$744$728$1,322
Total Curr. Assets$54,407$27,956$43,664$71,312
Property Plant & Equip (Net)$1,328$1,385$2,570$3,641
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$12,540$16,123$21,877$34,266
Tax Assets$0$0$0$0
Other NC Assets$632$89$129$236
Total NC Assets$14,500$17,597$24,576$38,143
Other Assets$0$0$0$0
Total Assets$68,907$45,553$68,240$109,455
Liabilities
Payables$2,582$1,525$1,976$1,565
Short-Term Debt$185$1,374$1,228$1,046
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$32,635$3,970$7,548$7,081
Total Curr. Liab.$35,402$6,869$10,752$9,692
LT Debt$937$0$1,373$2,601
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$937$0$1,373$2,601
Other Liabilities$0$0$0$0
Cap. Leases$1,122$1,374$2,601$3,647
Total Liabilities$36,339$6,869$12,125$12,293
Equity
Pref Stock$0$0$0$0
Common Stock$7$5$5$5
Retained Earnings-$397,010-$334,717-$307,688-$266,381
AOCI-$1,288-$967-$563$1,869
Other Equity$430,859$374,363$364,361$361,669
Total Equity$32,568$38,684$56,115$97,162
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$68,907$45,553$68,240$109,455
Net Debt-$7,618-$11,246-$10,558-$59,811